1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 01 DECEMBER 2014

CNS Drug News 01 DECEMBER 2014

  • December 2014
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - FDA-Approved Hysingla ER Places Pressure On Zohydro ER
Industry Brief - Cynapsus Reports Positive Top-Line Phase II Results For Off Episodes In PD
Industry Trend Analysis - AstraZeneca/Lilly's Alzheimer's Phase II/III Study Is High Risk/High Reward
Industry Brief - Forward Pharma Sues Biogen Idec Over Tecfidera Sales In Germany
Industry Brief - Pharmsynthez Completes First Patient Cohort In MyeloXen Phase II Study For MS
Industry Brief - Forward Pharma Receives Issue Notification For Erosion Matrix Patent In US
Industry Brief - Isis Initiates ISIS-SMNRx Phase III Study In Children With SMA; Earns Milestone
Industry Brief - Bio Blast's Cabaletta Receives FDA ODD For SCA3
Industry Brief - EMA Grants Treeway's TW001 ODD For ALS
Industry Brief - Soliris Granted ODD In Japan For NMO
Industry Brief - IntelGenx Settles US Bupropion Litigation With Wockhardt
Industry Trend Analysis - Mallinckrodt Sues After FDA Casts Doubt On Concerta Generics
Industry Brief - Janssen Submits NDA To FDA For Three-Month Paliperidone Palmitate
Industry Brief - First Patient Enrolled In Phase III Trial Of ITI-007 For Schizophrenia
Industry Brief - Insys' Pharmaceutical CBD Receives FDA ODD For Paediatric Schizophrenia
Industry Brief - Highland Receives Second NoA For Patent On HLD-200
Industry Trend Analysis - Avanir's Inhaled Migraine Therapy Is Delayed But Will Gain FDA Approval
Industry Brief - BfArM Accepts Rizaport MAA For Review
Industry Brief - Trevena Reports Positive Top-Line Results From TRV130 Phase IIa/b Study
Industry Brief - Camurus/Braeburn Sign Exclusive Licence For Long-Acting Buprenorphine Injectables
Industry Brief - NICE Issues Positive Final Guidance For Selincro
Industry Brief - Enrolment Completed In Probuphine Phase III Study For Opioid Dependence
Industry Brief - UCB/Daiichi Sankyo To Jointly Commercialise Lacosamide In Japan
Industry Brief - Eisai Launches Fycompa In Hong Kong
Industry Brief - Supernus Files Topiramate Lawsuit Against Zydus
Industry Brief - Orexigen Receives Allowance Of New US Patent For Contrave
Industry Brief - Two Additional US Patents Issued For Vivus' Qsymia
Industry Brief - Otsuka To Acquire Avanir Pharmaceuticals
Industry Brief - Wiinberg Resigns As CEO Of Lundbeck
Industry Brief - Bukwang Acquires Danish Bio-Venture Contera Pharma
Industry Brief - Shire To Relocate Over 500 Jobs To Massachusetts; Interim CFO Appointed

Table Of Contents

CNS Drug News 01 DECEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.